In a report released today, Cory Kasimov from Evercore ISI maintained a Hold rating on Moderna, with a price target of $28.00. According to TipRank......

RBC Capital analyst Luca Issi reiterated a Hold rating on Moderna yesterday and set a price target of $25.00. The company’s shares closed yesterday......

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics announced the results of its 2025 Annual General Meeting, highlig......

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics announced significant progress at its 2025 Annual General Meeting, ......

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has announced significant changes to its Board of ......

The Vanguard S&P 500 ETF ($VOO) gained 0.36% on Wednesday, snapping a four-day slide. The ETF is also up 1.10% in pre-market trading today after Nv......

Moderna ($MRNA) steps into Thursday’s analyst day with more pressure than momentum. The stock is down more than 40% this year and over 85% in three......

Analysts fell to the sidelines weighing in on Cartesian Therapeutics (RNAC – Research Report) and Galmed Pharmaceuticals (GLMD – Research Report) w......

The SPDR S&P 500 ETF Trust ($SPY) closed 0.02% lower on Friday. Volatility in the technology sector and concerns about a potential delay in Federal......

In a report released today, Martin Fan from Wedbush maintained a Buy rating on Cartesian Therapeutics, with a price target of $38.00. Fan covers th......